SciELO - Scientific Electronic Library Online

 
vol.19 número11Aportación científica de la medicina interna hospitalaria gallega a congresos nacionales e internacionales de su especialidadEstenosis de la arteria mesentérica superior como causa de isquemia crónica intestinal: Tratamiento percutáneo como alternativa terapéutica índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Anales de Medicina Interna

versión impresa ISSN 0212-7199

Resumen

ANGULO, E. et al. Comparation of antihypertensiva activity of fosinopril and irbesartan. An. Med. Interna (Madrid) [online]. 2002, vol.19, n.11, pp.29-33. ISSN 0212-7199.

Objective: To compare the antihypertensive effect of two daily single dose drugs acting on the renin-angiotensin axis by two different ways. Methods: Thirty patients were randomized to receive either irbesartan (150 mg once daily) (n=15, mean age 65.2±8.7 years, 9 men and 6 women) or fosinopril (20 mg once daily) (n=15, mean age 57.4±11.5 years, 4 men and 11 women, difference are not significant) during 12 weeks. When needed, hydroclorothiazide (12,5 mg) was added to treatment to improve hypotensive response.  Results: A reduction of SBP and DBP was observed in bothl treatment groups throughout the study. In order to obtain further BP reduction, hydrochlorothiazide was added to 6 patients with inadequate BP response at the 4th week (3 patients in the irbesartan group) and 8th week (2 patients in irbesartan group and 1 patient in fosinopril group). SBP was reduced in irbesartan group from 157.7 ± 11.2 to 131.0 ± 8.7 mmHg (12th week, p < 0.001). DBP decreases from 94.1 ± 5.6 to 82.7 ± 4.2 mmHg (p < 0.001). In fosinopril group SBP was reduced from 147.9 ± 11.7 to 132.2 ± 12.4 mmHg (p < 0.001) and DBP decreases from 92.3±6.3 to 84.0±5.4 mmHg (p < 0.001). Final between group differences in BP are not significant. Final BP reduction in irbesartan group (26.7 ± 11.6 mmHg) was bigger than that obtained in fosinopril group (15.6 ± 11.6 mmHg, p=0.011). BP reduction was significant in fosinopril group from the first month (SBP 140.7 ± 12.2, p=0,021; DBP 87.2 ± 6.2, p=0.003). In irbesartan group BP reduction was not significant until the second month (SBP 135.5 ± 10.4, p<0.001; DBP 85.3 ± 4.3, p<0.001). Conclusions: Fosinopril and irbesartan seems to be equally efective to reduce DBP. Irbesartan might have higher effectiveness on systolic blood pressure. Irbesartan act more gradually than fosinopril and this may be useful to prevent from acute blood pressure falls. 

Palabras clave : Hypertension; Treatment; Renin-angiotensin axis.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons